These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2919633)

  • 1. Remission of chronic idiopathic myelofibrosis to busulphan treatment.
    Manoharan A
    Am J Med Sci; 1989 Feb; 297(2):133. PubMed ID: 2919633
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission of chronic idiopathic myelofibrosis to busulfan treatment.
    Chang JC; Gross HM
    Am J Med Sci; 1988 May; 295(5):472-6. PubMed ID: 3376991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of polycythemia vera during chronic idiopathic myelofibrosis].
    Paladini G; Tosato F; Mazzanti G; Covaz E
    Minerva Med; 1985 Dec; 76(49-50):2315-7. PubMed ID: 4088526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to busulphan treatment of paroxysmal nocturnal hemoglobinuria and myelofibrosis in one and the same patient.
    Almquist A; Holm J; Wahlin A
    Acta Med Scand; 1981; 209(1-2):133-5. PubMed ID: 7211483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Onset of polycythemia in idiopathic myelofibrosis. Description of a clinical case and review of the literature].
    Pagano L; Teofili L; Marra R; Storti S; Rabbitti C; Leone G; Bizzi B
    Minerva Med; 1988 Jan; 79(1):51-4. PubMed ID: 3277085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case].
    Uemura Y; Iwahara Y; Kataoka R; Muneishi H; Miyoshi I
    Rinsho Ketsueki; 1990 Sep; 31(9):1553-6. PubMed ID: 2246832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelofibrosis: response to busulfan after hydroxyurea failure.
    Naqvi T; Baumann MA
    Int J Clin Pract; 2002 May; 56(4):312-3. PubMed ID: 12074218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis.
    Manoharan A; Pitney WR
    Scand J Haematol; 1984 Nov; 33(5):453-9. PubMed ID: 6515328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myelobromel in the treatment of patients with idiopathic myelofibrosis during erythremic phase].
    Komiva NF
    Probl Gematol Pereliv Krovi; 1970 Jan; 15(1):50-3. PubMed ID: 5420384
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
    Buhr T; Büsche G; Choritz H; Länger F; Kreipe H
    Am J Clin Pathol; 2003 Jan; 119(1):152-8. PubMed ID: 12520711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
    Comhaire F; Van Hove W; Van Ganse W; Van der Straeten M
    Scand J Respir Dis; 1972; 53(5):265-73. PubMed ID: 4508954
    [No Abstract]   [Full Text] [Related]  

  • 12. [Liver damage during use of busulfan].
    Adang RP; Breed WP
    Ned Tijdschr Geneeskd; 1989 Jul; 133(30):1515-8. PubMed ID: 2797253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Schmitt-Gräff A; Hülsemann R; Diehl V
    Histol Histopathol; 2004 Jan; 19(1):239-50. PubMed ID: 14702192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of myeloproliferative diseases.
    Sellei C
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lung changes under busulfan therapy in a case of chronic myelosis].
    Kolarz G; Pietsehmann H; Regele H
    Zentralbl Allg Pathol; 1970; 113(5):539-44. PubMed ID: 5289458
    [No Abstract]   [Full Text] [Related]  

  • 16. Myelofibrosis.
    Malpas JS
    Proc R Soc Med; 1968 May; 61(5):499. PubMed ID: 5655243
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current therapeutic possibilities in idiopathic myelofibrosis. Observations on 47 cases].
    Perugini S; Ascari E; Fontana G
    Clin Ter; 1968 Apr; 45(1):21-60. PubMed ID: 4897957
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tactics of cytostatic therapy of primary and secondary (post-erythremic) myelofibrosis].
    Demidova AV; Sysoeva NA
    Probl Gematol Pereliv Krovi; 1976 Jul; 21(7):23-7. PubMed ID: 1071792
    [No Abstract]   [Full Text] [Related]  

  • 19. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
    Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
    Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of osteomyelosclerosis and osteomyelofibrosis].
    Treske U
    Dtsch Med Wochenschr; 1970 Aug; 95(33):1691-2. PubMed ID: 5447788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.